Journal of Cellular Cancer

ISSN 2475-2037 (Online)

Menu
  • Home
  • About Journal
    • Aims and Scope
    • Time Lines
    • Copyright
    • Publication Ethics
    • Permanency of Content
    • Statement of informed consent
    • Subscription
    • Terms and conditions of purchase
  • Editors
  • Guides
    • Guide for Authors
    • Guidance for Peer Reviewers
    • Article processing charges
    • Protection of Human Subjects and Animals
    • Conflict of Interest
    • Publishing Process
    • Registration of Trials
  • Submit Manuscript
  • Current Issue
  • Archive
  • Contact Us
Menu

Tag: chemotherapy

Continuous bevacizumab plus second line chemotherapy beyond progression during or after maintenance bevacizumab

Posted on June 17, 2016August 23, 2016 by bm-jcc

http://dx.doi.org/10.18081/jcc/016-06/12-23 Journal of Cellular Cancer  Volume 8, Issue 1, pages 12-23 Received January 28, 2016; accepted May 21, 2016; published June 17, 2016 Haider Y. Shukur1* Abstract Bevacizumab has FDA approval in the first and second line treatment combined with chemotherapy of epithelial ovarian cancer (EOC). Data is lacking on survival outcomes in patients who…

Read more

Bibliographic Details

Bibliographic Details
Journal of Cellular Cancer
Journal Abbreviation: JCC
DOI: 10.18081/jcc.date.pages

ISSN 2475-2037
Manuscript Service: jcc.manuscript@bm-jcc.net

Archives

2024© Journal Management System. BM